NASDAQ · EVGN
Healthcare · Biotechnology
$0.56
Up+$0.00 (+0.36%)
Updated Aug 22, 2026, 1:39 PM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
EVGN closed at $0.56 after 21 trading sessions, up 3.69% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $0.5437 | $0.58 | $0.5412 | $0.5625 | 1.04M |
| Aug 20, 2026 | $0.60 | $0.60 | $0.5492 | $0.5605 | 228.34K |
| Aug 19, 2026 | $0.5914 | $0.6118 | $0.5652 | $0.6009 | 151.81K |
| Aug 18, 2026 | $0.56 | $0.5861 | $0.541 | $0.5826 | 151.19K |
| Aug 17, 2026 | $0.6163 | $0.6265 | $0.5409 | $0.56 | 345.9K |
| Aug 14, 2026 | $0.65 | $0.665 | $0.5905 | $0.6008 | 371.96K |
| Aug 13, 2026 | $0.65 | $0.6861 | $0.6251 | $0.651 | 408.75K |
| Aug 12, 2026 | $0.67 | $0.6726 | $0.59 | $0.6119 | 481.03K |
| Aug 11, 2026 | $0.682 | $0.7022 | $0.657 | $0.7005 | 362.38K |
| Aug 10, 2026 | $0.7111 | $0.80 | $0.56 | $0.6323 | 7.32M |
| Aug 7, 2026 | $0.709 | $0.7199 | $0.5878 | $0.6001 | 615.26K |
| Aug 6, 2026 | $0.6845 | $0.72 | $0.6604 | $0.685 | 374.29K |
| Aug 5, 2026 | $0.631 | $0.6386 | $0.6116 | $0.631 | 186.08K |
| Aug 4, 2026 | $0.55 | $0.6757 | $0.5401 | $0.65 | 464.34K |
| Aug 3, 2026 | $0.488 | $0.57 | $0.45 | $0.536 | 239.21K |
| Jul 31, 2026 | $0.493 | $0.535 | $0.4635 | $0.471 | 68.97K |
| Jul 30, 2026 | $0.51 | $0.51 | $0.4682 | $0.4894 | 70.98K |
| Jul 29, 2026 | $0.521 | $0.521 | $0.4781 | $0.4817 | 70.53K |
| Jul 28, 2026 | $0.539 | $0.539 | $0.4898 | $0.4945 | 77.31K |
| Jul 27, 2026 | $0.54 | $0.5539 | $0.5081 | $0.52 | 95.15K |
| Jul 24, 2026 | $0.559 | $0.559 | $0.531 | $0.5425 | 30.94K |
The latest Smart Investors Daily articles mentioning EVGN.
EVGN research
Company profile and research snapshot.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 22, 2025 | Lake Street | Buy | — |
| Aug 23, 2024 | Lake Street | Buy | — |
| Oct 2, 2023 | Alliance Global Partners | Buy | — |
| Aug 18, 2023 | Lake Street | Buy | — |
| Jul 21, 2023 | Roth MKM | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 15, 2026
AgPlenus Ltd., a company developing novel, sustainable crop protection products and a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), today announced the launch of its Antifungal Potency Predictor (APP). This new
Yahoo · Jul 9, 2026
The partnership will connect Evogene’s AI-based ChemPass AI with the BCDD’s laboratory infrastructure.
Yahoo · Jul 8, 2026
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational chemistry company focused on the generative design of small molecules for the pharmaceutical and agricultural industries, and the Blavatnik Center for Drug Discovery (BCDD) at Tel Aviv University, today announced a strategic joint initiative aimed at accelerating the growth, development, and success of innovation originating from Israel's academic research ecosystem and focused on small-molecule drug discovery. This collaboration
SeekingAlpha · Mar 5, 2026
Evogene Ltd. (EVGN) Q4 2025 Earnings Call March 5, 2026 9:00 AM ESTCompany ParticipantsOfer Haviv - CEO, President & DirectorYaron Eldad - Chief...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning EVGN.
